Drug intelligence / Profile preview

MT-110

Development stage: Preclinical
Lead developer: Myosin Therapeutics
Modality: Small Molecules

Overview

MT-110 is a clinical candidate small molecule inhibitor that selectively targets non-muscle myosin II (NMII) over cardiac muscle myosin II (CMII). Developed through rational drug design, it exhibits excellent properties, including high brain penetration. MT-110 has demonstrated efficacy in preclinical models for methamphetamine use disorder (MUD), a condition currently lacking FDA-approved therapies, and is considered a promising therapeutic agent.

Targets

MYH10 (Non-muscle myosin IIB)

Beyond the preview

Go deeper on MT-110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MT-110.

Explore the full profile